3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Myelodysplastic Syndromes
5
Hodgkin Disease
5
Leukemia, Biphenotypic, Acute
4
Hematologic Neoplasms
4
Leukemia, Myelomonocytic, Chronic
3
Anemia, Refractory, with Excess of Blasts
3
Sarcoma
2
Rhabdomyosarcoma
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Glioblastoma
2
Burkitt Lymphoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Teratoma
1
Solid Tumors
1
Sarcoma, Ewing
1
Rhabdoid Tumor
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Interventions
Etoposide
4
Cisplatin
4
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
fludarabine
2
Cyclophosphamide
2
Bleomycin
2
repotrectinib
1
pegfilgrastim
1
etoposide phosphate
1
copper dotatate CU-64
1
Watchful Waiting
1
Vorinostat
1
Teniposide
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Respiratory Physiological Phenomena
1
Practice Guidelines as Topic
1
Platinum
1
Nivolumab
1
Mesna
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Injections
1
Immunotherapy
1
Filgrastim
1
Drug Therapy
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms, Germ Cell and Embryonal
×
Filgrastim
×
Clear all
NCT02582697
2025-06-15
P3BEP
University of Sydney
Phase 3
Recruiting
500 enrolled